Das Online Archiv der CME Zeitschrift Nuklearmedizin

Von der effektiven Dosis in der Diagnostik zur patientenspezifischen Dosimetrie in der nuklearmedizinischen Therapie

Zeitschrift:	Nuklearmedizin
ISSN:	0029-5566
DOI:	http://dx.doi.org/10.3413/nukmed-2011060001
Ausgabe:	2011 (Vol. 50): Heft 6 2011 (221-246)
Seiten:	221-223

Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962; 87: 171-182.
Buckley SE, Chittenden SJ, Saran FH et al. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma. J Nucl Med 2009; 50: 1518-1524. DOI:10.2967/jnumed.109.064469
Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation. National Research Council, Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. Washington, D.C.: The National Academies Press 2006.
Dewaraja YK, Schipper MJ, Roberson PL et al. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. J Nucl Med 2010; 51: 1155-1162. DOI:10.2967/jnumed.110.075176
Eberlein U, Broer JH, Vandevoorde C et al. Biokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine - a review. Eur J Nucl Med Mol Imaging 2011; doi: 10.1007/s00259-011-1904-z.
Flux GD, Haq M, Chittenden SJ et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010; 37: 270-275. DOI:10.1007/s00259-009-1261-3
Geworski L, Schaefer A, Knoop BO et al. Physical aspects of scintigraphy-based dosimetry for nuclear medicine therapy. Nuklearmedizin 2010; 49: 85-95. DOI:10.3413/nukmed-0283
Hellwig D, Grgic A, Kotzerke J, Kirsch CM. Nuclear Medicine in Germany. Key data from official statistics. Nuklearmedizin 2011; 50: 53-67. DOI:10.3413/Nukmed-0380-11-01
ICRP. Publication 53: Radiation Dose to Patients from Radiopharmaceuticals. Ann ICRP 1987; 18 (1-4).
ICRP. Publication 60: 1990 recommendations of the International Commission on Radiological Protection. Ann ICRP 1991; 21 (1-3).
ICRP. Publication 80: Radiation dose to patients from radiopharmaceuticals: Addendum 2 to ICRP publication 53. Ann ICRP 1998; 28 (3).
ICRP. Publication 103: The 2007 recommendations of the International Commission of Radiological Protection. Ann ICRP 2007; 37 (2-4).
ICRP. Publication 106: Radiation dose to patients from radiopharmaceuticals: Addendum 3 to ICRP Publication 53. Ann ICRP 2008; 38 (1-2).
Krieger H. Strahlungsmessung und Dosimetrie Wiesbaden: Vieweg + Teubner 2011.
Lassmann M. Dosimetry of short-ranged radionuclides. Nuklearmedizin 2010; 49 (Suppl): S46-S49.
Lassmann M, Brans B, Behr T. Introduction 1st International Symposium on Radionuclide Therapy and Radiopharmaceutical Dosimetry. Cancer Biother Radiopharm 2005; 20: 45-46. DOI:10.1089/cbr.2005.20.45
Lassmann M, Chiesa C, Flux G, Bardies M. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging 2011; 38: 192-200. DOI:10.1007/s00259-010-1549-3
Matthay KK, Panina C, Huberty J et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with 131I-MIBG. J Nucl Med 2001; 42: 1713-1721.
Strigari L, Benassi M, Chiesa C et al. Dosimetry in nuclear medicine therapy: radiobiology application and results. Q J Nucl Med Mol Imaging 2011; 55: 205-221.
Strigari L, Sciuto R, Rea S et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med 2010; 51: 1377-1385. DOI:10.2967/jnumed.110.075861
Verburg FA, Lassmann M, Mader U et al. The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients. Eur J Nucl Med Mol Imaging 2011; 38: 673-680. DOI:10.1007/s00259-010-1689-5